---
title: "SETFIRST LIMITED — Ownership Dossier"
canonical: https://whiteintel.dev/entity/c3d8f5a8-81f6-5054-8112-e2ec1616323f
json: https://whiteintel.dev/api/public/dossier/c3d8f5a8-81f6-5054-8112-e2ec1616323f
identifier: oo:GB-COH-02332323
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# SETFIRST LIMITED

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-02332323`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/c3d8f5a8-81f6-5054-8112-e2ec1616323f  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/c3d8f5a8-81f6-5054-8112-e2ec1616323f  

## Cross-source identity

The same real-world entity, resolved across sources:

- **SETFIRST LIMITED** — GLEIF · `lei:549300TUPSIH7NLZWQ91` — https://whiteintel.dev/entity/83946b86-f8a8-5dec-8865-c09321c713af
- **Setfirst Limited** — source · `gb-coh:2332323` — https://whiteintel.dev/entity/b2825d29-b940-410d-8d9b-0af637177e29

## Ownership & control

### Owners / controllers

- **Glaxosmithkline Finance Plc** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/c4260dcc-2978-4402-9aeb-307778f2117e

### Holdings / subsidiaries

- **STIEFEL LABORATORIES (U.K.) LTD** (beneficial owner) — 75% — https://whiteintel.dev/entity/4c7c40dc-b177-5d25-b406-366d1b74d7b2
- **HALEON UK HOLDINGS LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/9a9412c4-bbf0-545c-b128-d5eba5dc2137
- **GLAXOCHEM (UK) UNLIMITED** (beneficial owner) — 75% — https://whiteintel.dev/entity/46d8b4aa-707c-5eb9-9076-c3707fc47642
- **SMITHKLINE BEECHAM (INVESTMENTS) LIMITED** (beneficial owner) — 50% — https://whiteintel.dev/entity/db7ed2ff-2d74-5d84-b66d-2ac4ad49b1db
- **GALVANI BIOELECTRONICS LIMITED** (beneficial owner) — 62.5% — https://whiteintel.dev/entity/6eb6ad0b-b135-5cdc-9b8c-b2e318ca8c32
- **SMITHKLINE BEECHAM (INVESTMENTS) LIMITED** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/db7ed2ff-2d74-5d84-b66d-2ac4ad49b1db

### UBO chain (walk to the ultimate owner)

A **11-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `02332323`
- **Status:** active
- **Type:** ltd
- **Incorporated:** 1989-01-03
- **Registered office:** 79 New Oxford Street, London, WC1A 1DG, United Kingdom
- **SIC:** 70100

### Officers

- EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED — corporate secretary · appointed 2002-01-18
- WALKER, Adam — director · British · appointed 2015-02-20
- EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED — corporate director · appointed 2001-03-02
- [GLAXO GROUP LIMITED](https://whiteintel.dev/entity/bc15a382-b626-4703-b25a-5893cefaa340) — corporate director · appointed 2001-03-02
- ADAMS, Deborah Anne — secretary · British · appointed 1993-10-15 · resigned 1996-01-17
- BANKS, Valerie — secretary · British · appointed 1996-01-17 · resigned 1998-05-18
- BRYANT, Karina Jane — secretary · British · appointed 1999-12-20 · resigned 2002-01-18
- COOMBER, Caroline Daphne — secretary · British · appointed 1998-05-18 · resigned 1999-12-20
- HORLER, Alison Marie — secretary · British · resigned 1993-06-02
- MCCLINTOCK, Clare Alexandra — secretary · British · appointed 1993-06-02 · resigned 1993-10-15
- SADLER, John — secretary · appointed 2020-06-09 · resigned 2022-07-29
- WILBRAHAM, Simon Nicholas — secretary · British · appointed 1998-09-04 · resigned 2001-03-02
- BALFOUR, Ian Main Ferguson — director · British · resigned 1994-01-01
- BLACKBURN, Paul Frederick — director · British · appointed 1999-07-15 · resigned 2001-03-05
- BONDY, Rupert — director · British · appointed 1998-09-07 · resigned 2001-03-05
- BONFIELD, Andrew Robert John — director · British · appointed 1998-09-07 · resigned 2000-12-27
- BROWN, Julie Belita — director · British · appointed 2023-05-01 · resigned 2025-07-19
- CROMPTON, Stephen Thomas — director · British · appointed 1998-09-07 · resigned 2001-03-05
- DAKERS, Christopher Hugh — director · British · appointed 1999-07-15 · resigned 2001-03-05
- DILLON, Alison Marie — director · British · appointed 1993-06-02 · resigned 1998-09-04

### Beneficial owners (Persons with Significant Control)

- [Glaxosmithkline Finance Plc](https://whiteintel.dev/entity/c4260dcc-2978-4402-9aeb-307778f2117e) — 75–100% shares · corporate PSC · United Kingdom — since 2016-04-06

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/02332323
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/02332323

## Get the full, resolved dossier (agent-callable)

The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent:

```bash
npx -y @whiteintel/mcp-server   # then: get_dossier · trace_ownership_path · check_offshore_exposure
```

Or unlock a one-off cited dossier for **SETFIRST LIMITED** — https://whiteintel.dev/entity/c3d8f5a8-81f6-5054-8112-e2ec1616323f · pricing https://whiteintel.dev/pricing.

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **SETFIRST LIMITED**. Human view: https://whiteintel.dev/entity/c3d8f5a8-81f6-5054-8112-e2ec1616323f · Structured JSON: https://whiteintel.dev/api/public/dossier/c3d8f5a8-81f6-5054-8112-e2ec1616323f._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._